ICAM‑1 ADC / Virtuoso Therap - LARVOL DELTA

A novel topoisomerase I inhibitor based anti-ICAM‑1 antibody drug conjugate for the treatment of hematologic malignancies and solid tumors (AACR 2023) - "Previous attempt to target ICAM‑1 with a monoclonal antibody bersanlimab (BI505, BioInvent) showed that it was well-tolerated but with limited clinical efficacy...Furthermore, in a repeat dose exploratory non-human primate safety study, the benchmark conjugate ICAM‑1‑DXd (DAR 8) was well-tolerated at 41 mg/kg, the highest dose tested. In conclusion, ICAM‑1 is an attractive target for topoisomerase I inhibitor based ADC and warrants further investigation."

Gastrointestinal Cancer • Hematological Malignancies • Liver Cancer • Lung Cancer • Lymphoma • Melanoma • Multiple Myeloma • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ICAM1

Virtuoso Therapeutics to Present Preclinical Findings on Three Best-in-Class Bispecific and ADC Programs at the 2023 American Association for Cancer Research (AACR) Annual Meeting (PRNewswire) - "Virtuoso Therapeutics...announced that it will present three posters highlighting the preclinical data from leading bispecific antibody and ADC programs at the American Associate for Cancer Research (AACR) 2023 Annual Meeting."

Preclinical • Colorectal Cancer • Gastrointestinal Cancer • Hematological Malignancies • Hepatocellular Cancer • Liver Cancer • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Skin Cancer • Small Cell Lung Cancer • Solid Tumor • Thoracic Cancer